Ganciclovir
- Generic Name
- Ganciclovir
- Brand Names
- Cytovene, Zirgan
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N5O4
- CAS Number
- 82410-32-0
- Unique Ingredient Identifier
- P9G3CKZ4P5
- Background
An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
- Indication
For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
- Associated Conditions
- CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis
A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir
- Conditions
- HIV InfectionsCytomegalovirus Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT00002251
- Locations
- 🇺🇸
Davies Med Ctr, San Francisco, California, United States
🇺🇸Georgetown Univ Med Ctr, Washington, District of Columbia, United States
An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002135
- Locations
- 🇺🇸
Roche Global Development - Palo Alto, Palo Alto, California, United States
Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections
- Conditions
- Cytomegalovirus InfectionsHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002024
- Locations
- 🇺🇸
Roche Global Development - Palo Alto, Palo Alto, California, United States
The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002299
- Locations
- 🇺🇸
UCI Med Ctr, Orange, California, United States
🇺🇸Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸USC, Los Angeles, California, United States
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
- Conditions
- Cytomegalovirus InfectionsHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 700
- Registration Number
- NCT00002095
- Locations
- 🇺🇸
Kraus - Beer Med Group, Los Angeles, California, United States
🇺🇸Beth Israel Hosp, Boston, Massachusetts, United States
🇺🇸UCSD, San Diego, California, United States
Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Schering-Plough
- Registration Number
- NCT00002070
- Locations
- 🇺🇸
Children's Hosp of San Francisco, San Francisco, California, United States
🇺🇸Pacific Presbyterian, San Francisco, California, United States
🇺🇸Dr Douglas Dieterich, New York, New York, United States
An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Roche Global Development
- Target Recruit Count
- 20
- Registration Number
- NCT00002015
- Locations
- 🇺🇸
Univ of Rochester Med Ctr, Rochester, New York, United States
🇺🇸Ctr for the Health Sciences / UCLA Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Chicago / Wylers, Chicago, Illinois, United States
A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT00002156
- Locations
- 🇺🇸
Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
🇺🇸Retina - Vitreous Associates Med Group, Los Angeles, California, United States
🇺🇸Univ of Illinois, Chicago, Illinois, United States
A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- American National Red Cross
- Registration Number
- NCT00001999
- Locations
- 🇺🇸
Georgetown Univ Med Ctr, Washington, District of Columbia, United States
A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS
- Conditions
- ColitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002273
- Locations
- 🇺🇸
Roche Global Development - Palo Alto, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.